DDAVP in acquired hemophilia A: case report and review of the literature.
One patient with an acquired factor VIII inhibitor is reported in which an acute lower intestinal hemorrhage was successfully managed using Desmopressin (DDAVP). The patient initially had a factor VIII level of 10% with a inhibitor titer of 1.9 Bethesda units. Following administration of DDAVP the factor VIII level rose to 86% and there was a decrease in the number and volume of bloody stools. The inhibitor disappeared following treatment with corticosteroids, however the patient ultimately expired due to complications of ischemic colitis. This case and 21 previously reported cases of acquired hemophilia treated with DDAVP are reviewed. The data support a role for DDAVP in the treatment of non life threatening hemorrhage in patients with acquired hemophilia and low titer factor VIII inhibitors (< 5 Bethesda units or factor VIII > or = 5%).
Mudad
R
R
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Kane
W H
WH
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000592:standards / Q000627:therapeutic use*; D005169:Factor VIII / Q000032:analysis / Q000037:antagonists & inhibitors; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007410:Intestinal Diseases / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
D000305:Adrenal Cortex Hormones; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin